Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

Gastroenterology

Volumn 154, Issue 4, 2018, Pages 989-997

  Liu, Chun Jen ^a   Chuang, Wan Long ^b   Sheen, I Shyan ^c   Wang, Horng Yuan ^d   Chen, Chi Yi ^e   Tseng, Kuo Chih ^f   Chang, Ting Tsung ^g   Massetto, Benedetta ^h   Yang, Jenny C ^h   Yun, Chohee ^h   Knox, Steven J ^h   Osinusi, Anu ^h   Camus, Gregory ^h   Jiang, Deyuan ^h   Brainard, Diana M ^h   McHutchison, John G ^h   Hu, Tsung Hui ^c   Hsu, You Chun ⁱ   Lo, Gin Ho ^j   Chu, Chi Jen ^k   Chen, Jyh Jou ^l   Peng, Cheng Yuan ^m   Chien, Ron Nan ^c   Chen, Pei Jer ^a   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^f DALIN TZU CHI HOSPITAL   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^h GILEAD SCIENCES   (United States)

ⁱ CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^j E DA HOSPITAL   (Taiwan)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l CHI MEI MEDICAL CENTER   (Taiwan)

^m CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

ALT; DAA; Immune Suppression; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LEDIPASVIR; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; VIRUS DNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; COLON HEMORRHAGE; COMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; KNEE MENISCUS RUPTURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; OPTIC NEURITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TAIWAN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DNA, VIRAL; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SUSTAINED VIROLOGIC RESPONSE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 85043256744     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.11.011     Document Type: Article

References (34)

1. Liu, C.J., Liou, J.M., Chen, D.S., et al. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 104 (2005), 783–791.
2. Sagnelli, E., Coppola, N., Messina, V., et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 36 (2002), 1285–1291.
3. Liu, C.J., Chen, P.J., Chen, D.S., Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 3 (2009), 517–525.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
5. Liu, C.J., Chuang, W.L., Lee, C.M., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136 (2009), 496–504.
6. Liu, C.J., Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. J Gastroenterol Hepatol 29 (2014), 26–30.
7. Collins, J.M., Raphael, K.L., Terry, C., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 61 (2015), 1304–1306.
8. Balagopal, A., Thio, C.L., Another call to cure hepatitis B. Clin Infect Dis 61 (2015), 1307–1309.
9. Takayama, H., Sato, T., Ikeda, F., et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 46 (2016), 489–491.
10. Ende, A.R., Kim, N.H., Yeh, M.M., et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep, 9, 2015, 164.
11. De Monte, A., Courjon, J., Anty, R., et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 78 (2016), 27–30.
12. Wang, C., Ji, D., Chen, J., et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15 (2017), 132–136.
13. Londoño, M.C., Lens, S., Mariño, Z., et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 45 (2017), 1156–1161.
14. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed March 24, 2017.
15. Gane, E.J., Hyland, R.H., Yang, Y., et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology 152 (2017), 1366–1371.
16. Gane, E., Hyland, R., An, D., et al. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther 21 (2016), 605–609.
17. World Health Organization WHO guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014; Geneva, Switzerland.
18. Sagnelli, E., Pasquale, G., Coppola, N., et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 32 (2004), 144–148.
19. Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
20. Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
21. US Food and Drug Administration, Center for Drug Evaluation and Research. Virology review, sofosbuvir and ledipasvir. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000MicroR.pdf. Accessed July 21, 2017.
22. Hoofnagle, J.H., Reactivation of hepatitis B. Hepatology 49 (2009), S156–S165.
23. Perrillo, R.P., Gish, R., Falck-Ytter, Y.T., American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 221–244.
24. Hwang, J.P., Lok, A.S., Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11 (2014), 209–219.
25. Di Bisceglie, A.M., Lok, A.S., Martin, P., et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology 61 (2015), 703–711.
26. Bersoff-Matcha, S., Cao, K., Jason, M., et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 166 (2017), 792–798.
27. Liu CH, Liu CJ, Su TH, et al. Minimal risk of hepatitis B virus reactivation in hepatitis B virus surface antigen-negative chronic hepatitis C patients receiving direct acting antiviral agents [Abstract 831]. Paper presented at: the 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016; November 11–15, 2016; Boston, MA.
28. Yu, M.L., Lee, C.M., Chen, C.L., et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 57 (2013), 2135–2142.
29. Wiegand, S.B., Jaroszewicz, J., Potthoff, A., et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect, 21, 2015, 710.
30. Wieland, S.F., Asabe, S., Engle, R.E., et al. Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver. J Virol 88 (2014), 5184–5188.
31. Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
32. Martin, B., Hennecke, N., Lohmann, V., et al. Restoration of HCV-specific CD8+T cell function by interferon-free therapy. J Hepatol 61 (2014), 538–543.
33. Thomas, D.L., Thio, C.L., Martin, M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 (2009), 798–801.
34. Mah, Y.H., Liu, C.H., Chen, C.L., et al. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. J Formos Med Assoc 115 (2016), 953–960.